On November 12, 2021 Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported it will host a virtual Key Opinion Leader (KOL) event regarding the potential treatment of pancreatic cancer utilizing Lantern Pharma’s drug candidate LP-184, on World Pancreatic Cancer Day, Thursday, November 18th at 12:00 pm EST (Press release, Lantern Pharma, NOV 12, 2021, View Source [SID1234595399]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will be cohosted by:
Dr. Igor Astsaturov, an established, NCI-funded, physician scientist and co-leader of the Marvin & Conchetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center
Dr. Ira Sharp, retired internal medicine specialist, as well as a pancreatic cancer survivor and cancer patient advocate
Dr. Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma
The event will feature discussions on the recent advances of LP-184, a PTGR1-activated small molecule that leverages DNA repair deficiency to selectively eradicate pancreatic cancers, and potential clinical uses of LP-184 in an upcoming Phase I clinical trial.
Lantern Pharma’s Virtual KOL Event details are as follows:
Thursday, November 18, 2021, 12:00 pm EST- 1:00 pm EST
To register for the webinar, please sign up here: View Source
A replay of the webinar will be available on the investor relations section of the Company’s website: ir.lanternpharma.com
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States with a five-year survival rate of 7.9% and a 10-year survival rate of just 1%. GLOBOCAN estimates that for pancreatic cancer there are approximately 490,000 new cases of pancreatic cancer globally on an annual basis, with over 62,000 of those cases occurring in North America. Due to the late onset of symptoms, patients are often diagnosed after the cancer has progressed to locally advanced or metastatic stages of the disease. LP-184 is designed to target a specific subset of pancreatic cancer patients that are genetically defined, which has the potential to increase beneficial therapeutic options for patients and may ultimately improve survival for those with this cancer.
LP-184 is in pre-clinical development for several targeted indications in cancer, including pancreatic cancer and glioblastoma. LP-184 preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mutations in DNA repair pathways. LP-184 was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer, and also for the treatment of glioblastoma multiforme (GBM) and other malignant gliomas.